Zepatier(elbasvir)
Zepatier (elbasvir) is a small molecule pharmaceutical. Elbasvir was first approved as Zepatier on 2016-01-28. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Zepatier
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Elbasvir
+
Grazoprevir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZEPATIER | Merck Sharp & Dohme | N-208261 RX | 2016-01-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zepatier | New Drug Application | 2019-12-11 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| chronic hepatitis c | EFO_0004220 | D019698 | B18.2 |
| hepatitis c | — | D006526 | B19.2 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ELBASVIR / GRAZOPREVIR, ZEPATIER, MSD SUB MERCK | |||
| 2024-12-09 | NPP | ||
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | B19.2 | 2 | 10 | 11 | 14 | 8 | 44 | |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | 1 | 9 | 5 | — | 15 |
| Hiv | D006678 | O98.7 | — | 1 | 3 | 1 | 1 | 6 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | 2 | 3 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | — | 2 | — | 3 |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 2 | 1 | 3 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | 1 | — | 2 |
| Intravenous substance abuse | D015819 | — | — | — | 1 | — | 1 | ||
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | 1 | — | 1 |
| Cross infection | D003428 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatocellular carcinoma | D006528 | C22.0 | — | 1 | 1 | — | — | 2 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 1 | — | — | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 2 | — | — | 2 |
| Hepacivirus | D016174 | — | 2 | 1 | — | — | 2 | ||
| Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | — | — | 1 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | 1 | — | — | — | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Deglutition disorders | D003680 | HP_0002015 | R13.1 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | 1 | — | — | — | — | 1 | ||
| Viral hepatitis human | D006525 | EFO_0004196 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | — | — | — | — | 1 | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ELBASVIR |
| INN | elbasvir |
| Description | Elbasvir is a complex organic heterotetracyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with grazoprevir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults. It has a role as an antiviral drug, a hepatoprotective agent and a hepatitis C virus nonstructural protein 5A inhibitor. It is a L-valine derivative, a member of imidazoles, a carbamate ester, a N-acylpyrrolidine, an organic heterotetracyclic compound and a ring assembly. |
| Classification | Small molecule |
| Drug class | antivirals: nonstructural protein 5A (NS5A) inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 1370468-36-2 |
| RxCUI | 1734628 |
| ChEMBL ID | CHEMBL3039514 |
| ChEBI ID | — |
| PubChem CID | 71661251 |
| DrugBank | DB11574 |
| UNII ID | 632L571YDK (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zepatier - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,795 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zepatier
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,481 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more